Article Open Access Published: 31 January 2020 Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models Marco Tamborrini
, Julia Hauser, Anja Schäfer, Mario Amacker, Paola Favuzza, Kwak Kyungtak, Sylvain Fleury & Gerd Pluschke npj Vaccines volume 5, Article number: 9 (2020) Cite this article 142 Accesses 4 Altmetric Metrics Acknowledgements Work at Swiss TPH has been co-funded by the Commission for Technology and Innovation, (grant 17635.1 PFLS-LS) and by Fondation Botnar (grant 6349). Mymetics SA provided the virosome formulations for the studies.
While in this first study unadjuvanted PfCyRPA influenza virosomes were tested, adjuvanted human-compatible formulations are under development that may offer the advantage to have both antigens and adjuvants bound to the same particle with no free-form adjuvant, improving the immunogenicity and safety profile of the vaccine.
rabbits were immunised three times and each dose consisted of 100?µg antigen and 200?µL AddaVax™ adjuvant
Market Data 
Markets 
AI
